about
High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis deltaHepatitis delta virus: a peculiar virusInterferon alpha for chronic hepatitis DInterferon-alpha for hepatitis DHepatitis delta: epidemiology, diagnosis and management 36 years after discoveryHepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an updateA multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet NamHepatitis D: Scenario in the Asia-Pacific region.Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional studyPrevalence and molecular characterization of hepatitis D virus in Saudi Arabia: A single-center study.Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in ItalyQuantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients.High prevalence of hepatitis delta virus among patients with chronic hepatitis B virus infection and HIV-1 in an intermediate hepatitis B virus endemic region.Prevalence of hepatitis D virus in hepatitis B virus infected patients referred to Taleghani hospital, Tehran, IranClinical presentation and genotype of hepatitis delta in KarachiUnderstanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modelingMolecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan.True prevalence of twin HDV-HBV infection in Pakistan: a molecular approachTreatment of chronic delta hepatitis: a nine-year retrospective analysis.Hepatitis A Virus among Drug Users and the Role of Vaccination: A ReviewClinical Features and Seroepidemiology of Anti-HDV Antibody in patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis.Hepatitis D Virus: Introduction and EpidemiologyTreatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.Phylogenetic analysis of HDV isolates from HBsAg positive patients in Karachi, Pakistan.Transcription factor YY1 and its associated acetyltransferases CBP and p300 interact with hepatitis delta antigens and modulate hepatitis delta virus RNA replication.HIV and Hepatitis B Virus Coinfection: Approach to Management: Case Study and Commentary.Bloodborne viral hepatitis infections among drug users: the role of vaccinationHepatitis D Virus: A Call to Screening.Chronic liver disease in Aboriginal North Americans.Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.End points of therapy in chronic hepatitis B.Diagnostic markers for hepatitis virus infection.Treatment of delta hepatitis.Hepatitis D virus infection in the Western Brazilian Amazon - far from a vanishing disease.Treatment options for hepatitis delta virus infection.Hepatitis delta virus inhibits alpha interferon signaling.Hepatitis delta: virological and clinical aspects.The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited.Action of inhibitors on accumulation of processed hepatitis delta virus RNAs.Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion.
P2860
Q21132282-35007936-D59F-451A-9AE9-CF056E3DC00FQ21284829-A389ACFC-F5FC-405D-B236-0C2A465B6CDBQ24234444-D9C53777-2BD0-4315-AB04-9FF2A8491C76Q24244385-8C6A94C5-8A93-4E6A-AAEE-3848544235F4Q26849602-E0B662DA-01DE-4487-A09A-3778852BF049Q28284989-6D65F9BE-28D9-41FD-898E-5F42323A88C8Q28480392-50AE2754-F447-44DD-96C8-8F89ACBD97A7Q33629416-D42E92C0-823E-4545-AEC7-CA9F5DB79C5AQ33734612-062C02A0-2AD1-46FB-A4B6-4B451C57D285Q33796525-C3F9A371-0139-449F-8F9C-00E48AB42B58Q33801300-47434EB2-E908-452E-9034-9CAFD57BB13BQ33859188-08909877-DCDB-4752-9E77-AE9967A842B7Q33967322-6028BA00-D4C2-41C5-9A00-CF1BA2C1ABADQ34031396-FE8E5309-782A-4A17-853A-3FA169B7B80DQ34098812-2C6BD02B-15ED-4C47-BE5B-221443452486Q34577514-7E87CA8D-1E94-4C14-B839-6399351F9CE5Q34740997-EEBCC4F7-2D4D-4708-901F-A8EAF5C3E1DAQ35231340-1C016447-EB1E-4BCB-B3E0-9666A8A15BA5Q35603743-2C7BFC07-94AD-4C9F-B06D-C4AC8DBBE5FFQ35747360-A2E0AD25-CF5B-432A-AC81-CB074ED1A502Q35764198-B950E8B7-7CC5-431B-B110-11E95528DA42Q35795551-67EA112D-4F85-4BFC-B081-5D4DDD3E02C0Q36357493-3D1F4F5D-395D-487E-9694-83BB805F4156Q36384122-D9DE496F-2672-4F8C-AC47-EF1F49578A7EQ36804532-222B20D9-585B-4186-BA57-7EC10A2991FBQ36916860-A0F604BD-C5C8-49DC-95BB-855B8276A54FQ37167103-8B99B22E-E558-4234-8BC4-653AFB274F35Q37182821-B222866E-5194-49BA-8F92-5D6F4FAEE64BQ37242565-8F78F1E8-60DD-4DBF-B61C-AFE7B1921CB5Q37278249-BB39C9B8-A5B1-4DD5-82CF-AB9DABC2529DQ37688129-9AEEAF6B-F1BB-4B5A-BF5A-FC033A358433Q38089735-670FF832-57F5-4FB4-91B0-25EEE4038EC2Q38102778-74E2A0EE-B4E0-4C08-9C44-A5D79098D49FQ38919437-F0565EDB-53EE-44F5-BD48-39717EBB100FQ39502937-08E4A078-7187-48D5-80E9-4C33454857F0Q39904698-E85BFCE2-6B1A-464A-8B10-154A8F1161B8Q40042818-549776B1-9B72-4B0E-A7A2-B2F7CAA6C0E1Q40051750-D3573F13-6A2C-4452-AE2E-F96071B545F8Q40305013-3F1B1F41-9F80-4CD5-B8D4-A50DBBB190FCQ40429700-D1CC0918-B581-49A6-9F76-B120C4F8C126
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Delta hepatitis: an update.
@ast
Delta hepatitis: an update.
@en
Delta hepatitis: an update.
@nl
type
label
Delta hepatitis: an update.
@ast
Delta hepatitis: an update.
@en
Delta hepatitis: an update.
@nl
prefLabel
Delta hepatitis: an update.
@ast
Delta hepatitis: an update.
@en
Delta hepatitis: an update.
@nl
P1476
Delta hepatitis: an update.
@en
P2093
Patrizia Farci
P304
P356
10.1016/S0168-8278(03)00331-3
P478
39 Suppl 1
P577
2003-01-01T00:00:00Z